Bard Associates
DMK

Bard Associates’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Bard Associates’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,773
Closed -$44K – 162
2020
Q1 		$44K Sell
1,773
-3
-0.2% -$127 0.03% 149
2019
Q4 		$87K Sell
1,776
-78
-4% -$3.78K 0.04% 151
2019
Q3 		$91K Sell
1,854
-83
-4% -$5.96K 0.05% 151
2019
Q2 		$176K Sell
1,937
-32
-2% -$3.89K 0.09% 141
2019
Q1 		$291K Sell
1,969
-35
-2% -$6.77K 0.15% 128
2018
Q4 		$316K Sell
2,004
-122
-6% -$23.4K 0.18% 123
2018
Q3 		$521K Sell
2,126
-43
-2% -$10.2K 0.24% 108
2018
Q2 		$486K Sell
2,169
-16
-0.7% -$4.28K 0.23% 117
2018
Q1 		$535K Buy
2,185
+27
+1% +$7.09K 0.27% 109
2017
Q4 		$665K Sell
2,158
-3
-0.1% -$987 0.32% 104
2017
Q3 		$790K Sell
2,161
-25
-1% -$8.87K 0.37% 98
2017
Q2 		$796K Hold
2,186
– – 0.36% 101
2017
Q1 		$650K Sell
2,186
-43
-2% -$10.8K 0.3% 103
2016
Q4 		$491K Sell
2,229
-28
-1% -$5.62K 0.23% 110
2016
Q3 		$542K Sell
2,257
-14
-0.6% -$2.91K 0.26% 105
2016
Q2 		$445K Sell
2,271
-61
-3% -$28.1K 0.24% 110
2016
Q1 		$1M Sell
2,332
-11
-0.5% -$3.93K 0.58% 72
2015
Q4 		$885K Sell
2,343
-156
-6% -$48.9K 0.52% 72
2015
Q3 		$677K Sell
2,499
-24
-1% -$6.68K 0.39% 86
2015
Q2 		$742K Sell
2,523
-51
-2% -$15.4K 0.37% 85
2015
Q1 		$710K Sell
2,574
-21
-0.8% -$9.07K 0.34% 92
2014
Q4 		$1.12M Buy
2,595
+85
+3% +$27K 0.52% 75
2014
Q3 		$822K Sell
2,510
-5
-0.2% -$1.47K 0.38% 87
2014
Q2 		$847K Buy
2,515
+73
+3% +$28.7K 0.34% 104
2014
Q1 		$1.09M Hold
2,442
– – 0.46% 86
2013
Q4 		$1.09M Buy
+2,442
New +$1.07M 0.46% 80

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Level Four Advisory Services
Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return

Bard Associates's DMK Position: Q2 2020 in Review

Bard Associates sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2020, closing a stake of 1,773 shares — an estimated $44K sold.

Bard Associates first reported a position in DMK in Q4 2013 and held it in 26 quarters. The position peaked at $1.12M in Q4 2014. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

  • Bard Associates reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2020 after selling out during the quarter.
  • Bard Associates sold 1,773 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2020, an estimated $44K.
  • Bard Associates first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 26 quarters.
  • Bard Associates's DMK Pharmaceuticals Corporation Common Stock position peaked at $1.12M in Q4 2014.
  • 47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2020.

Based on Bard Associates's 13F filing for Q2 2020, filed 13 Aug 2020.